secwatch.observer — SEC 8-K summary
======================================

Issuer:     Altimmune, Inc. (ALT)
CIK:        0001326190
Form:       8-K
Filed at:   2023-02-28T23:59:59+00:00
Accession:  0001326190-23-000003
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Altimmune Q4 2022 net loss $21.7M; cash $184.9M; pemvidutide obesity interim readout expected March 2023
--------------------------------------------------------------------------------

- Net loss for Q4 2022 was $21.7M ($0.43 per share) vs $23.9M ($0.57) in Q4 2021; revenue negligible.
- Cash, cash equivalents and short-term investments totaled $184.9M at December 31, 2022.
- R&D expenses $19.2M in Q4 2022, including $13.4M for pemvidutide and $1.9M for HepTcell.
- MOMENTUM Phase 2 obesity trial 24-week interim readout expected in March 2023; Phase 2b NASH trial initiation expected mid-2023.
- HepTcell Phase 2 enrollment >90% complete; data readout expected first half 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1326190/000132619023000003/0001326190-23-000003-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1326190/000132619023000003/alt-20230228x8k.htm
  HTML page:      https://secwatch.observer/filing/0001326190-23-000003

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer